MorphoSys AG (MOR.DE)
XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
As of 01:03PM CEST. Market open.
| Previous Close | 66.10 |
| Open | 66.00 |
| Bid | 66.70 x 1500 |
| Ask | 66.90 x 8800 |
| Day's Range | 66.00 - 67.00 |
| 52 Week Range | 14.52 - 68.00 |
| Volume | |
| Avg. Volume | 423,030 |
| Market Cap | 2.521B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.53 |
| Earnings Date | Apr 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 56.00 |
Business WireMorphoSys AG Reports First Quarter 2024 Financial Results
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
ACCESSWIREMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety ...
ZacksNovartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
© 2024 Yahoo. All rights reserved.